Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).
1 finding from 1 review
Serious adverse effects · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Significant adverse effects: significant bleeding requiring intervention, severe pain, iatrogenic injury · adult patients who underwent primary endoscopic sinus surgery, with a diagnosis of recurrent acute or chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).
1 finding from 1 review
Serious adverse effects · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in serious adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported.
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse effects compared with topical ciclosporin; GRADE not reported.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in withdrawal due to adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Adverse effects · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
Alitretinoin showed no clear difference in proportion of participants with adverse effects ‐ measured over 24… compared with placebo (moderate certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes treatment‐related adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Adverse event nausea and vomiting (0 to 24 hours) · people with traumatic hyphema
Systemic aminocaproic acid probably leads to higher adverse effects: nausea or vomiting compared with placebo (moderate certainty).
1 finding from 1 review